Immuneering Corporation has announced plans to hold a virtual Investor Event in early January 2025. The event will focus on discussing data from the company's ongoing Phase 2a trial of IMM-1-104, a universal-RAS/RAF medicine aimed at treating broad populations of cancer patients. The data to be presented includes:
- Additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer.
- Initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer.
- Initial data from IMM-1-104 monotherapy in second-line pancreatic cancer.
In addition to these, the company will also provide initial PK, PD, and safety data from the Phase 1 portion of its Phase 1/2a trial of IMM-6-415. Details on how to access the Investor Event will be provided in due course.
Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering, expressed excitement about sharing additional data from the Phase 2a study of IMM-1-104, highlighting the urgent need for new treatment options for pancreatic cancer patients. The FDA has granted IMM-1-104 Orphan Drug designation in pancreatic cancer, along with Fast Track designations in first and second-line pancreatic cancer, and advanced melanoma.
Immuneering Corporation is a clinical-stage oncology company focused on developing universal-RAS/RAF medicines for cancer patients, with an initial aim to develop a universal-RAS therapy. The company's approach involves Deep Cyclic Inhibition of the MAPK pathway, aiming to impact cancer cells while sparing healthy cells. IMM-1-104, the company's lead product candidate, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial for patients with advanced solid tumors, including those with RAS mutations. IMM-6-415, another product candidate, is an oral, twice-daily Deep Cyclic Inhibitor also in a Phase 1/2a trial for patients with advanced solid tumors harboring RAS or RAF mutations.
